AzTrials
AzTrials

Chronic Obstructive Pulmonary Disease (COPD)BiRDNCT07648082

Breathlessness Perceptions Within Respiratory Diseases

An observational study of Chronic Obstructive Pulmonary Disease (COPD) and Asthma (Diagnosis), run by University Hospitals, Leicester at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Read more about this study

Who is it for?
Ages 18 to 100 yearsHealthy volunteers can take part
How many people
75 participants
Where
1 siteUnited Kingdom
Study dates
6 Jun 2025to 1 Jul 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study population consists of a healthy group and a disease group. The disease group will have a known respiratory condition such as COPD, Asthma, ILD or Bronchiectasis. The healthy group will not have any functionally limiting conditions interms, cardiorespiratory and muskuloskeletal.

Who may be able to join

  • • Aged 18 or over up to 100
  • Known respiratory diagnosis* OR Healthy control**
  • Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale
  • Able to communicate in English
  • Able to attend two study visits
  • Able to provide written informed consent
  • Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD.
  • Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.

Who cannot join

  • • Unstable disease or undergoing investigations for unexplained symptoms
  • Undergone a surgery within past six weeks
  • Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc)
  • BMI ≥ 35kg/m2
  • Unable to communicate in English
  • Unable to provide written informed consent
  • Unable to abstain from smoking for 8 hours prior to testing

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Enya Dr. Daynes, PhD contact

0116 273 0333 ext. +44

e.daynes@nhs.net

Iridu Udanthi Basnayake, MSc contact

0116 273 0333

iub3@leicester.ac.uk

United Kingdom1 site, 1 recruiting
  • Glenfield Hospital

    Leicester, Leicestershire, LE3 9QP

    Enya Daynes, PhD, +44 1162730333 ext. +44, e.daynes@nhs.net

    Enya Daynes, PhD

    Recruiting

Other trials in United Kingdom

About this study

Official title: Exploring Differences in Breathlessness Perceptions Within Respiratory Diseases

Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Therefore, this study aims to understand the influences of physiology, psychology, function and breathing pattern on health related quality of life in those with a respiratory disease compared to healthy controls. This project is a cross-sectional cohort study including those with a known respiratory disease and experiencing breathlessness, compared to non-breathless healthy controls. The investigators will measure your physiology through spirometry (a breathing test that tells us about their lung function), psychology through questionnaires, function through an exercise test and breathing pattern using opto-electrictronic plethysmography (markers are placed on your chest to see how participants breathe while exercising). This will be conducted over two visits. The investigators will recruit participants from clinics at the University Hospitals of Leicester NHS Trust. The investigators are aiming to recruit 50 participants with a respiratory disease and 25 healthy controls. The results of this study will help us understand breathlessness in more detail in order to be able to develop better treatments.

Read the detailed description

Breathlessness is a debilitating symptom that results in poorer quality of life, increased hospitalisations, and increased mortality. Breathlessness is a complex multi-dimensional sensation with established bio-psycho-social influences (Hayen et al., 2013) that are likely to interact, though the mechanisms or relative contributions of these interactions are unknown (Oxley \& Macnaughton, 2016). Breathlessness is a hallmark feature of respiratory disease and is the primary reason for seeking healthcare advice and treatments. Though currently breathlessness management follows a one-size fits all approach and does not pay consideration to the unique and individual experience of breathlessness.

The breathing thinking functioning (BTF) model of breathlessness is a theoretical framework that attempts to explain this complex and multifactorial symptom, however it lacks scientific premise. Highlighting that physiology, psychology and function will all play a role in determining breathlessness for the individual. An additional complication, that is seldom explored is disordered breathing patterns. This is potentially bi-directional where by severe breathlessness could contribute to disordered breathing and/or disordered breathing could lead to severe breathlessness. There is currently no objective marker of disordered breathing pattern however, use of optoelectronic plethysmography (OEP) has shown promise in quantifying this phenomenon (Smyth, 2021). OEP is a novel technique, utilising 3-dimensional motion capture, and can be measured during exercise, using a cardiopulmonary exercise testing, which allows for monitoring of breathlessness and breathing pattern during exercise, commonly reported as troublesome by patients. OEP has been used in Chronic Obstructive Pulmonary Disease to assess hyperinflation, though evidence within respiratory disease is at its infancy, and has not been explored alongside other factors to understand the contribution of multiple factors of breathlessness. Therefore, there is a current gap in the literature exploring the interaction(s) of factors contributing to breathlessness severity, including the objective analysis of breathing pattern. Further understanding the breathlessness in this way could lead to personalisation or treatments increasing their effectiveness, and improving health and quality of life. The project will quantitatively measure breathlessness perception, alongside objective cardiorespiratory measures and background health and well-being data as well as OEP breathing pattern data (such as compartment contribution and inter-compartment asynchrony). This will allow an understanding of how each of these factors may affect interventions and differences in breathlessness experience and presentation, and subsequently the acceptability of breathlessness.

Keywords
Breathlessness, OEP, Cardiopulmonary Exercise Testing, Respiratory diseases, Heart rate variability, Breathing patterns
Medical subject headings
Pulmonary Disease, Chronic Obstructive, Asthma, Disease, Lung Diseases, Interstitial, Bronchiectasis, Dyspnea, Respiratory Tract Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07648082
Study groupRoleWhat they receive
50 participants with a respiratory disease and 25 health controls will be recruited.Inclusion criteria is: * Aged 18 or over up to 100 * Known respiratory diagnosis* OR Healthy control** * Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale * Able to communicate in English * Able to attend two study visits * Able to provide written informed consent * Known respiratory diagnosis could include, but is not limited to, Chronic Obstructive Pulmonary Disease, Asthma,Bronchiectasis or Interstitial Lung Disease. * Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal. Participants are excluded if,: * Unstable disease or undergoing investigations for unexplained symptoms * Undergone a surgery within past six weeks * Contraindications for exercise outlined by American College of Sports Medicine guidelines (Unstable Cardiovascular disease, hypertension etc) * Body Mass Index ≥ 35kg/m2 * Unable to communicate in English * Unable to provide consent

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Breathing pattern regional contribution parameters

    Optoelectronic plethysmography allows to quantify how different thoracic compartments contribute to the overall tidal volume through regional contribution parameters. These regional contributions are expressed as percentages.

    Measured: From June 2025 to July 2026

Secondary outcomes (31)
  1. Breathing pattern-Timing parameters-Recording duration

    The duration will be recorded in minutes and seconds to state how long a specific measurement lasted.

    Measured: From June 2025 to July 2026

  2. Breathing pattern-Timing parameters- Sampling frequency rate

    This is one of the core timing parameter. The system uses sample at 60-120 Hz (frames per second).

    Measured: From June 2025 to July 2026

  3. Breathing pattern-Timing Parameters- Number of respiratory cycles analysed

    This parameter is important to give an indication of data adequacy. It will be reported in whole numbers.

    Measured: From June 2025 to July 2026

  4. Breathing pattern-Ratio parameters-Compartmental contributions

    All the parameters will be expressed as percentages. (%RCp, %RCa and %AB) typically ranging from (0-100%)

    Measured: From June 2025 to July 2026

  5. Breathing pattern- Phase angle parameters

    These parameters will be meausred by the degree ranging from 0 to 180 (Complete paradox)

    Measured: From June 2025 to July 2026

  6. Breathing pattern-ratio parameters- Temporal ratios

    This will be reported in decimal values. (Ti/Ttot, Ti/Te ratio, IE ratio inverse of Ti/Te) Ti-Inspiratory time Te-Expiratory time Ttot-Total breath duration

    Measured: From June 2025 to July 2026

  7. Rate of Perceived Exertion (RPE) and Borg breathlessness scale

    Provides details about how breathlessness one feels and how hard the exercise is during exercise . Both these scales will be reported in numbers. The RPE is from 6-20 and the Borg scale is from 0-10. Higher scores will indicate worst breathlessness and exertion from the performing exercise.

    Measured: From June 2025 to July 2026

  8. Spirometry

    Lung Function parameters such as FEV1 -Forced Expiratory Volume, FVC -Forced Vital Capacity, FEV1/FVC ratio will be obtained using Spirometry (Spirotrac). Presented in litres can be converted to percentage. Depending on the guidelines usually if the FEV1/ FVC ratio<= 0.7 it can be said that there is an airway obstruction. Lower value indicates a higher level of breathlessness. The GOLD classification criteria is usually used to describe the severity. The values can further be explained as obstructive or restrictive by looking at the FVC%. A lower FVC% predicted will indicate worse restriction.

    Measured: From June 2025 to July 2026

  9. Modified Medical Research Council Dyspnea Scale (mMRC)

    Scale that grades the severity of breathlessness based on the level of physical activity that provokes the symptom. The scale is from 0-4. Lower values indicate less severity of breathlessness while higher values indicate severe breathlessness.

    Measured: From June 2025 to July 2026

  10. Dysponea-12 (D-12)

    The Dyspnoea-12 (D-12) is a patient-reported outcome measure designed to assess the multidimensional nature of breathlessness severity through both physical and affective components. The questionnaire has 12 questions where the participant will be asked to put a tick to any box from none, mild, moderate and severe.

    Measured: From June 2025 to July 2026

  11. Hospital Anxiety and Depression Scale (HADS)

    Self-report questionnaire designed to screen for clinically significant anxiety and depression in medical populations. The participant will be asked to underline their answers for all the questions. The questionnaire includes a 'A' category and a 'D' category. Scores are given to both catergories from 0-3. At the end the two catergoeies will be calculated separately.

    Measured: From June 2025 to July 2026

  12. Breathlessness catastrophising scale (BCS)

    A measure designed to assess catastrophic thinking patterns specifically related to breathlessness. BCS is a 13 item questionnaire where the participant will have to tick one of the boxes for each question starting from not at all, to a slight degree, to a moderate degree, to a great degree and all the time.

    Measured: From June 2025 to July 2026

  13. Euroqol 5-Domain-5-Level (EQ5D-5L)

    A standardised generic health-related quality of life instrument designed to provide a simple, comprehensive measure of health status across diverse populations and conditions. The questionnaire asseses 4 sections where the participant will have to select one option from each section. The questionnaire is assessing the health related quality of life interms of that day and not in general. At the end of the questionnaire there is a separate scale from 0-100 where the participant will have to place an x mark on the scale and write that score in a box which will indicate how they feel on that specific day.

    Measured: From June 2025 to July 2026

  14. Nijmegen Questionnaire (NQ)

    An instrument designed to assess symptoms associated with hyperventilation syndrome and dysfunctional breathing patterns. The questionnaire contains 16 symptoms. The participant will be required to place a tick in one of the boxes for each question. Answers include, never, rarely, sometimes, often and very often.

    Measured: From June 2025 to July 2026

  15. Breathing pattern assessment tool (BPAT)

    Visible characteristics of breathing patterns during rest where the participant will be asked to rest against a back seat. The participant will be observed for 1 minute by a member of the study team where they will have to breathe in and out as they usually do. During that time the team member will observe whether the breathing is rhythmical, whether the participant is using using their chest, abdomen or both for breathing, whether their inspiratory and expiratory flows are silent, audible or loud. Other questrions that will be answered by the team member would be channel of inspiration and expiration, air hunger, rhythm as well the team member will also calculate the respiratory rate within a 1 minute. Scores will be given from 0-2 and at the end the total score will be calculated.

    Measured: From June 2025 to July 2026

  16. Cardiopulmonary Exercise testing -Gas Exchange Parameters

    Peak Oxygen Uptake (VO2 peak) meausured through mL/min or L/min, If >=85 is normal, 65-84 is mildly reduced, 50-64 is moderately reduced and <50 is severely reduced.

    Carbon Dioxide Output (VCO2) and RER (VCO2/VO2) meausured through mL/min or L/min, VCO2 roughly rises parallel to VO2. The volume of CO₂ produced per minute by the body reflects the metabolic CO₂ production from aerobic and anaerobic metabolism combined. The respiratory exchange ratio which is RER gives a clear indication whether the test was maximal effort or not.

    RER >=1.10 is the key cutoff.

    AT will all be meausured through mL/min or L/min. Normal: typically > 40% of predicted VO₂ max, or ≥ 11 ml/kg/min Higher AT = better - indicates the body can sustain aerobic metabolism at higher workloads before switching to anaerobic system.

    Measured: From June 2025 to July 2026

  17. Cardiopulmonary Exercise Testing- Ventilatory Parameters (Minute Ventilation)

    Minute Ventilation will be measured at maximal exercise. The measures will be stated in L/min. Minute ventilation is assess the ventilatory capacity. Usually the ventilatory reserve utilizes <60 to 70% of the maximum voluntary ventilation which is considered healthy.

    Measured: From June 2025 to July 2026

  18. Cardiopulmonary Exercise Testing- Ventilatory Parameters (Tidal Volume)

    Tidal Volume will be measured by L or mL. It is amount of air that moves in and out of the lung. During exercise, it increases linearly before plateauing indicating whether a participant's exercise capacity is physically restricted due to lung mechanics.

    Measured: From June 2025 to July 2026

  19. Cardiopulmonary Exercise Testing- Ventilatory Parameters ( Respiratory Rate)

    This is measured by breaths per minute. The amount of breaths taken will indicate how your brain and lungs are functioning to clear the carbondioxide which will help to maintain the chemical balance.

    Resting phase 12 to 20 breaths/min -Baseline range Peak Exercise 35 to 45 breaths/min -Normal physiological range for healthy adults.

    Measured: From June 2025 to July 2026

  20. Cardiopulmonary Exercise Testing-Ventilatory Parameters (MVV and BR)

    MVV- Maximal Voluntary Ventilation and BR-Breathing Reserve both are measured by L/min. This determines whether a patient's exercise capacity is limited by their lungs or by their heart and/or muscles. MVV represents a participants absolute ceiling for breathing capacity, while BR measures how much of that capacity is left over at peak exercise. If MVV >=80% it is considered good and if <80% it is considered bad. Whereas for BR, if >11L/min is considered as the lungs still having more capacity left after exercising and <=11L/min is considered that the patient is exhausted and their breathing capacity has reached the limit.

    Measured: From June 2025 to July 2026

  21. Cardiopulmonary Exercise Testing- Ventilatory Efficiency Parameters

    VE/VO2 slope and VE/VCO2 at AT are measured by a dimensionless ratio. VE/VCO2 is considered good when it is between 23-30 and bad when it is >34. VE/VO2 is considered good when it is between 25 to 33 and bad when it is >36

    Measured: From June 2025 to July 2026

  22. Cardiopulmonary Exercise Testing-HR reserve

    This will be measured through bpm. It is the difference between predicted maximum heart rate and the actual peak heart rate. <15bpm indicates a good response whereas >=15bpm indicates a poor response.

    Measured: From June 2025 to July 2026

  23. Cardiopulmonary Exercise Testing- Work Rate

    This will be reported in W (Watts). Achieving >= 80% of the predicted work rate is considered a good response whereas <80% would be considered as a poor response.

    Measured: From June 2025 to July 2026

  24. Oxygen Saturation

    This will be reported through % (Percentage). 95-100%- Good 93-94%- Borderline <92%- Bad

    Measured: From June 2025 to July 2026

  25. Blood pressure

    This will be measured by mmHg Before the test (At rest) >=200/110- Contraindication not to perform the exercise test <90/60- Too low for the baseline

    During the exercise test, If the systolic value exceeds 190 or 210 indicates a severe hypertension A critical stop would be a systolic value exceeding 250 or a diastolic value exceeding 115.

    After the test, The blood pressure should return to near or actual borderline taken during rest.

    Measured: From June 2025 to July 2026

  26. Height

    Measured through cm.

    Measured: From June 2025 to July 2026

  27. Weight

    Measured by kg (Kilograms).

    Measured: From June 2025 to July 2026

  28. Body Mass Index

    Calculated manually via height and weight measurements. Will be presented as kgm squared. This study has a cut off value which is not involving participants above 35.

    Measured: From June 2025 to July 2026

  29. Heart rate variability (HRV) - Holter Monitor

    SDNN- Standard Deviation of normal-to-normal R-R intervals, SDANN-Standard Deviation of the mean R-R intervals, RMSSD-Square root of the mean squared difference of successive R-R intervals are all measued by milliseconds (ms).

    Measured: From June 2025 to May 2026

  30. Heart Rate Variability-Holter Monitor

    LF-Low Frequency Power and HF-High Frequency Power are both measured by milliseconds squared or absolute units.

    LF Absolute 300 to 1500- considered good LF Absolute <100 -considered bad/abnormal

    HF Absolute 200 to 1000- considered good HF Absolute <50- considered bad/abnormal

    Measured: From June 2025 to July 2026

  31. Heart Rate Variability-Holter Monitor

    LF/HF ratio will be a dimensionless ratio represented without any units. High rates will suggest of sympathetic predominance.

    At rest Good range will be 1.0-2.0 Bad range >5 or <0.5

    Measured: From June 2025 to July 2026

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2026
  2. Study start6 Jun 2025
  3. Primary completion1 Jul 2026 (estimated)
  4. Study completion1 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
75 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07648082
Sponsor's protocol ID
172675
Other IDs
NIHR203327
Acronym
BiRD
Status last verified
Jun 2026
First submitted
31 Dec 2025
Last updated
15 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Once participnats enrolled the data were anonymised. All the outcome measure data will be made available and kept within a locked UHL cabnited and password protected computer for future study purposes.

Publications

  • Pritchard A, Burns P, Correia J, Jamieson P, Moxon P, Purvis J, Thomas M, Tighe H, Sylvester KP. ARTP statement on cardiopulmonary exercise testing 2021. BMJ Open Respir Res. 2021 Nov;8(1):e001121. doi: 10.1136/bmjresp-2021-001121.

    PubMed 34782330
  • Oxley R, Macnaughton J. Inspiring change: humanities and social science insights into the experience and management of breathlessness. Curr Opin Support Palliat Care. 2016 Sep;10(3):256-61. doi: 10.1097/SPC.0000000000000221.

    PubMed 27490147
  • Hayen A, Herigstad M, Pattinson KT. Understanding dyspnea as a complex individual experience. Maturitas. 2013 Sep;76(1):45-50. doi: 10.1016/j.maturitas.2013.06.005. Epub 2013 Jul 10.

    PubMed 23849705

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Obstructive Pulmonary Disease (COPD) and Asthma (Diagnosis), run by University Hospitals, Leicester at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Enya Dr. Daynes, PhD (0116 273 0333 ext. +44, e.daynes@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Breathing pattern regional contribution parameters (time frame: From June 2025 to July 2026). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07648082, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in